2015

Proctor D, Suh M, Thompson C, Hixon, G. Inhalation cancer risk assessment of titanium dioxide. Presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

View Abstract

Harris MA, Thompson CM, Proctor DM, Suh M, Wolf JC, Seiter JM, Chappell MA, Haws LC. Analysis of duodenal crypt health following exposure to Cr(VI) in drinking water. Presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

View Abstract

Thompson CM, Young RR, Suh M, Dinesdurage H, Elbekai R, Harris MA, Rohr AC, Proctor DM. Hexavalent chromium does not induce mutations in the oral mucosa of transgenic Big Blue® rats following drinking water exposures at a carcinogenic dose. Presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

View Abstract

2014

Wu C, Fortier KJ, LaPensee K, Fan W, Mitchell M, Cyr PL, Jensen IS. A US hospital economic impact model for oritavancin in ABSSSI patients with risk of MRSA infections. Abstract PSS10, ISPOR 17th Annual European Congress 2014.

View Abstract

Meddings J, Saint S, Krein S, Gaies E, Reichert H, Hickner A, McNamara S, Mody L. Systematic review of interventions to reduce catheter-associated urinary tract infection in the long-term care setting. Presented at ID Week, Philadelphia, PA, October 2014.

Erichsen R, Kelsh MA, Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Taipei, Taiwan, October 28–30, 2014.

Reichert H, McMahon LF, Meddings J. Risk-adjusting hospital-acquired pressure ulcer rates from administrative data: How do hospitals perform by the risk-adjusted AHRQ Patient Safety Indicator 3 compared to a proposed measure using risk-standardization applied by the Centers for Medicare and Medicaid Services for other outcomes? Presented at the Academy Health Annual Research Meeting, San Diego, CA, June 2014.

Jensen IS, Bay C, Cyr PL. Estimating the impact of combining cangrelor and bivalirudin to a U.S. hospital performing PCI procedures. ISPOR 18th Annual International Meeting, New Montreal Quebec, 2014.

Jensen IS, Wu C, Bay CB, Cyr PL. Estimating the clinical value of cangrelor in patients undergoing PCI. International Academy of Cardiology, 19th World Congress on Heart Disease, Boston, MA, 2014.

Wu C, Fortier K, Fan WJ, LePensse K, Bay CB, Cyr PL, Jensen IS. A U.S. hospital budget impact model for oritivancin in ABSSSI patients with risk of MRSA infections. ISPOR 16th Annual European Congress, Amsterdam, Netherlands, 2014.